抗精神病药物市场报告：2031 年趋势、预测与竞争分析

由于思觉失调症、失智症、躁郁症和忧郁症市场存在机会，全球抗精神病药物市场前景光明。预计到 2031 年，全球抗精神病药物市场规模将达到 220 亿美元，预计 2025 年至 2031 年期间的复合年增长率为 5.8%。这个市场的主要驱动力是精神障碍盛行率的上升和人们对精神健康的认识的不断提高。

• Lucintel 预测，在预测期内，第二代将继续成为治疗层级中最大的细分市场。
• 从应用角度来看，由于思觉失调症盛行率不断上升，思觉失调症将继续成为最大的细分市场。
• 从地区来看，由于精神保健服务的采用率不断提高以及人口老化速度加快，预计北美将在预测期内继续成为最大的地区。

抗精神病药物市场的策略性成长机会

抗精神病药物市场在各种应用领域提供了许多成长机会。透过利用这些机会，相关人员可以加强服务提供并满足对精神疾病有效治疗日益增长的需求。

• 对新型抗精神病药物的需求日益增长精神疾病盛行率的上升推动了对新型抗精神病药物的需求。为了满足这个新兴市场的需求，创新研发的需求日益增长。
• 关注儿童精神病学：将抗精神病治疗扩展到儿童具有巨大潜力。开发适合年龄的剂型和治疗方法可以满足可能患有一系列精神疾病的年轻族群的需求。
• 精神病远端医疗服务：远距精神病学服务的扩展有助于填补精神健康保健的空白。此类服务提高了患者的参与度，特别是那些难以接触到的人群，并透过与精神科医生透过即时视讯连结进行后续会诊，促进了治疗依从性。
• 综合护理模式：支持综合护理模式（尤其是慢性病护理模式）的趋势日益增长，该模式将药物治疗与其他常见的患者照护方法相结合。这种方法加强了精神卫生专业人员和初级卫生保健系统之间的联繫，为患者提供更好、更全面的照护。
• 向新兴市场的全球扩张：向新兴市场的扩张代表着抗精神病药物产业的重大成长机会。透过根据当地需求客製化产品和行销策略，我们可以改善医疗服务并扩大一系列治疗方法的市场。

此类成长策略有望促进抗精神病药物市场的发展，改善患者的治疗效果，并增加基本精神卫生服务的可用性。

抗精神病药物市场的驱动因素与挑战

各种驱动因素​​和挑战影响抗精神病药物市场，包括技术改进、经济问题和监管方面。如果相关人员想要在如此复杂的行业中取得成功，了解这些因素非常重要。

抗精神病药物市场受以下因素驱动：

• 提高对精神疾病的认识：儘管精神病残障人士被视为耻辱，但对精神疾病药物的需求仍然很大，寻求抗精神病药物治疗的人数激增。工作人员和大众媒体的参与鼓励人们寻求医疗，从而进行更多的检测和更快的诊断。
• 药物开发过程中的新兴趋势：新的药物传递方法和配方，例如长效注射剂，正在提高治疗依从性，从而增加药物使用。
• 医疗保健基础设施发展：一些地区医疗保健结构的改善带来了更好的精神卫生服务，从而导致抗精神病药物的使用增加。
• 监管发展：有关简化药品审批流程的不断发展的法规正在促进抗精神病药开发新药，加剧了该行业的竞争。
• 精神疾病的增加：由于世界各地精神障碍病例的增加，需要开发有效的药物来治疗精神病，从而促进该市场的成长。

抗精神病药物市场面临的挑战包括：

• 对心理健康问题的认识：儘管人们的认识不断提高，但对精神疾病的耻辱感仍然是市场成长的主要障碍。
• 新治疗方法的成本：开发新药思觉失调症药物的高成本为中小企业设置了障碍，阻碍了市场竞争和创新。
• 监管障碍：复杂且耗时的监管要求可能会延迟新药和生物相似药的上市进程，从而为製造商和市场参与企业带来不确定性。

应对这些挑战对于改善治疗结果和为患者提供更好的抗精神病药物至关重要。克服耻辱感、高成本、监管环境和市场饱和等障碍将改善治疗结果并改善整体心理健康护理状况。

目录

第一章执行摘要

第二章全球抗精神病药物市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章 2019年至2031年市场趋势及预测分析

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球抗精神病药物市场趋势（2019-2024）及预测（2025-2031）
• 全球抗精神病药物市场（依治疗层级）
  • 第一代
  • 第二代
• 全球抗精神病药物市场（按分销管道）
  • 医院药房
  • 零售药局
  • 网路药局
• 全球抗精神病药物市场（按应用）
  • 思觉失调症
  • 失智
  • 躁郁症
  • 忧郁症
  • 其他的

第四章2019年至2031年区域市场趋势与预测分析

• 按地区划分：全球抗精神病药物市场
• 北美抗精神病药物市场
• 欧洲抗精神病药物市场
• 亚太地区抗精神病药物市场
• 世界其他抗精神病药物市场

第五章 竞争分析

• 产品系列分析
• 业务集成
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球抗精神病药物市场按治疗层级的成长机会
  • 全球抗精神病药物市场按分销管道分類的成长机会
  • 按应用：全球抗精神病药物市场的成长机会
  • 按地区划分：全球抗精神病药物市场的成长机会
• 全球抗精神病药物市场的新趋势
• 战略分析
  • 新产品开发
  • 全球抗精神病药物市场容量不断扩大
  • 全球抗精神病药物市场的合併、收购和合资企业
  • 认证和许可

第七章主要企业简介

• Alkermes
• Eli Lilly and Company
• Bristol-Myers Squibb
• Otsuka Holdings
• AbbVie
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Pfizer
• Astrazeneca
• Dr. Reddy's Laboratories

The future of the global antipsychotic drug market looks promising with opportunities in the schizophrenia, dementia, bipolar disorder, and depression markets. The global antipsychotic drug market is expected to reach an estimated $22 billion by 2031 with a CAGR of 5.8% from 2025 to 2031. The major drivers for this market are the rise in the prevalence of mental disorders and growing awareness regarding mental health.

• Lucintel forecasts that, within the therapeutic class category, second-generation will remain the larger segment over the forecast period.
• Within the application category, schizophrenia will remain the largest segment due to an increase in incidences of schizophrenic disorders.
• In terms of regions, North America will remain the largest region over the forecast period due to a rise in adoption of mental healthcare services and a surge in the aging population.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Antipsychotic Drug Market

The antipsychotic drug market has undergone a structural change induced by various emerging trends. These trends highlight changes in treatment habits, growing technologies, and the disease burden of patients, with the ultimate goal of making therapies more effective and improving patients' quality of life.

• Personalized Medicine: More pharmacogenomic testing to prevent relapse is being utilized when treating antipsychotics, as the era of personalized medicine has arrived. This approach aims to maximize potency and minimize observable adverse effects, ensuring better compliance and outcomes.
• Digital Health Integration: With advancements in telehealth systems and mobile applications, it has become easier to manage antipsychotic therapy. These tools allow for more active surveillance of treatment, support compliance, and provide better access to healthcare professionals for improved management.
• Long-Acting Injectable Formulations: Chronic patients with schizophrenia show better compliance with initiation and maintenance treatment due to the introduction and increased use of long-acting injectable antipsychotics (LAIs). LAIs reduce the burden of daily pill intake, which can lead to the violence associated with non-compliance, making the overall treatment more effective.
• Focus on Co-Occurring Conditions: Patients with psychotic disorders often have other comorbid conditions such as anxiety and depression. There is a growing realization that these must be addressed. The trend toward concurrent treatment of such disorders is becoming more common, contributing to overall patient care.
• Regulatory Evolution: The changing regulatory environment is flattening drug development timelines, leading to more drugs entering the antipsychotic market. This results in new drugs becoming available more rapidly, which increases competition and ultimately improves treatment options for patients.

These trends are redefining the antipsychotic drug market by providing more individualized and holistic treatment. If these trends persist, they will likely improve treatment outcomes and enhance patient satisfaction, especially for those with a complex variety of mental health disorders.

Recent Developments in the Antipsychotic Drug Market

Important developments have defined the antipsychotic drug market, enhancing treatment and patient care. Several other developments are changing the course of history, including technological advancements, regulatory changes, and evolving attitudes toward mental health.

• New Drug Approvals: There has been an increasing approval of new antipsychotic medications, along with favorable changes in their safety profiles, opening new avenues for patient treatment. New drugs are developed to treat specific symptoms and benefit patients who do not respond well to standard therapies.
• Emergence of Generic Formulations: The availability of generic antipsychotic pharmaceuticals is making it easier and more affordable for patients to receive treatment. This is especially important in low-income countries where the cost of essential drugs can be a major barrier to access.
• Advancements in Delivery Methods: The introduction of new drug administration techniques, such as long-acting injectables, is helping patients with chronic mental illness comply with treatment. These products help reduce the need for daily medication intake, minimizing relapse cases.
• Governments Working to Improve Access and Financing of Mental Health Services: Many governments are implementing policies to improve access to mental health care and resources. Such initiatives promote clearer diagnoses and approaches toward mental health disorders.
• Disease Management: There is an increase in the use of collaborative care models, where mental health care is provided alongside primary care. This integrated approach allows for both physical and mental health needs to be addressed in a single visit.

These developments are pushing the antipsychotic drug market forward, improving patient outcomes, and expanding the availability of mental health services.

Strategic Growth Opportunities for Antipsychotic Drug Market

The antipsychotic drug market presents numerous opportunities for growth across various applications. By taking advantage of these opportunities, stakeholders can enhance service provision and respond to the increasing need for effective treatments for mental health disorders.

• Increasing Need for New Antipsychotic Drugs: The demand for new antipsychotic therapeutics is driven by the rising prevalence of mental illnesses. There is a growing demand for innovative research and drug development to meet the needs of this expanding market.
• Focus on Pediatric Psychiatry: There is significant potential in expanding antipsychotic treatment to pediatric populations. Developing age-appropriate dosage forms and treatment methods will cater to the needs of this young group, who may experience a range of mental health disorders.
• Telepsychiatry Services: The expansion of telepsychiatry services is helping bridge gaps in mental health care. These services increase patient participation, particularly among hard-to-reach populations, and facilitate adherence to treatment through follow-up sessions with psychiatrists via live video link.
• Integrated Care Models: There is a growing trend toward integrated care models that combine drug treatment with other common methods of patient care, particularly in support of the chronic care model. This approach strengthens the connection between mental health workers and the primary healthcare system, providing better and more holistic care to patients.
• Global Expansion into Emerging Markets: Expanding into emerging markets presents a significant growth opportunity for the antipsychotic drug industry. Tailoring products and marketing strategies to local needs can improve access to treatment and expand the market for various therapies.

These growth strategies will push the antipsychotic drug market forward, improving patient outcomes and increasing the availability of essential mental health services.

Antipsychotic Drug Market Driver and Challenges

Various drivers and challenges impact the antipsychotic Drug market such as technological improvements, economic issues, and regulatory aspects. It is important to understand these factors if stakeholders want to succeed in such a complicated occupation.

The factors responsible for driving the antipsychotic drug market include:

• Increasing Consciousness of Mental Disorders: Despite being a consolation to the stigma attributed to mentally challenged persons, medicines for psychosis are in demand, and antipsychotic treatment seeking is also burgeoning. Staff and mass media involvement is making people seek health care more which leads to more testing and faster diagnosis.
• Emerging Trends In The Drug Development Process: New approaches to drug delivery and formulation such as long-acting injectables are resulting in better adherence to treatment and therefore growth in the use of the drug.
• Development Of Healthcare Infrastructure: There have been upgrades in the healthcare structure in several places enabling better mental health services hence the use of antipsychotic drugs.
• Regulatory Favor: Regulatory evolution concerning simplification of the drug licensing process has led to positive enhancement of the development of new antipsychotic drugs increasing competition within the industry.
• Rising Incidence Of Mental Health Disorders: The increased cases of mental disorders among many people in the world are making it necessity to develop potent medications for psychotic disorders which enhance the growth of this market.

Challenges in the antipsychotic drug market are:

• Perception of Mental Health Problems: Despite increased awareness, mental illness stigma remains a significant barrier to growth in the market.
• Cost of New Treatment Approaches: The high cost of developing and promoting new drugs for schizophrenia can be a barrier for smaller companies, hindering competition and innovation in the market.
• Regulatory Barriers: The process of bringing new drugs and biosimilars to market can be delayed due to complex and time-consuming regulatory requirements, creating uncertainty for manufacturers and market participants.

Addressing these challenges is essential for improving treatment outcomes and ensuring the availability of better antipsychotic drugs for patients. Overcoming obstacles such as stigma, high costs, regulatory hurdles, and market saturation will increase the effectiveness of treatments and enhance the overall mental health care landscape.

List of Antipsychotic Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies antipsychotic drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antipsychotic drug companies profiled in this report include-

• Alkermes
• Eli Lilly and Company
• Bristol-Myers Squibb
• Otsuka Holdings
• AbbVie
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Pfizer
• Astrazeneca
• Dr. Reddy's Laboratories

Antipsychotic Drug by Segment

The study includes a forecast for the global antipsychotic drug market by therapeutic class, distribution channel, application, and region.

Antipsychotic Drug Market by Therapeutic Class [Analysis by Value from 2019 to 2031]:

• First-generation
• Second-generation

Antipsychotic Drug Market by Distribution Channel [Analysis by Value from 2019 to 2031]:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Antipsychotic Drug Market by Application [Analysis by Value from 2019 to 2031]:

• Schizophrenia
• Dementia
• Bipolar Disorder
• Depression
• Others

Antipsychotic Drug Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Antipsychotic Drug Market

The antipsychotic drug market has seen favorable changes due to rising global awareness of mental health, advancements in drug development technologies, and a changing regulatory environment. Countries like the United States, China, Germany, India, and Japan are experiencing steady developments, including drug approvals, new treatment options, and expanded mental health services. These trends reflect a growing understanding of the importance of mental health and appropriate treatment.

• United States: In the U.S., the antipsychotic drug market has seen multiple new drug approvals, including long-acting injectable drugs that improve patient compliance. The new generation of medicines is being developed alongside functional genomics tools that help tailor antipsychotic medications to specific patients. Telepsychiatry has also gained widespread acceptance, improving access to mental health care, especially during the COVID-19 pandemic. These trends are enhancing patient outcomes by addressing primary mental health conditions and comorbid factors.
• China: The antipsychotic drug market in China has experienced rapid growth due to increased recognition of mental health issues and government emphasis on mental health programs. The market has been further supported by the emergence of generic versions of popular antipsychotic drugs, making treatment more affordable. Reforms in mental health policy and staff training are improving diagnosis and care. Additionally, technologies like digital health are assisting in patient monitoring and follow-up care.
• Germany: The antipsychotic drug market in Germany has progressed positively with the development of novel drugs and improvements in the regulatory process. These new drugs, which have better side effect profiles, are attracting interest in the market. Germany's healthcare system emphasizes evidence-based treatment protocols and psychosocial rehabilitation while increasing budget allocations and community awareness initiatives are improving societal response to antipsychotic treatments.
• India: The antipsychotic drug market in India is poised for significant growth due to the high prevalence of mental disorders and the decreasing stigma associated with mental health issues. Efforts to develop mental health care through policy initiatives and partnerships with NGOs are supporting market growth. The introduction of low-cost generics is also increasing access to antipsychotic medications. Awareness programs aimed at stigma reduction and early treatment are improving patient compliance.
• Japan: The antipsychotic market in Japan is characterized by innovation, particularly in products targeting symptoms of schizophrenia and bipolar disorder. Recent amendments to drug approval laws have expedited the availability of new treatments, improving the landscape for mental health care. The use of bipolar disorder medications, combined with cognitive behavioral therapy (CBT) and support groups, is on the rise. Furthermore, the use of telemedicine and mobile apps is helping enhance patient adherence and improve treatment efficacy.

Features of the Global Antipsychotic Drug Market

Market Size Estimates: Antipsychotic drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: Antipsychotic drug market size by therapeutic class, distribution channel, application, and region in terms of value ($B).

Regional Analysis: Antipsychotic drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapeutic class, distribution channels, applications, and regions for the antipsychotic drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the antipsychotic drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the antipsychotic drug market by therapeutic class (first-generation and second-generation), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), application (schizophrenia, dementia, bipolar disorder, depression, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Antipsychotic Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Antipsychotic Drug Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Antipsychotic Drug Market by Therapeutic Class
  • 3.3.1: First-generation
  • 3.3.2: Second-generation
• 3.4: Global Antipsychotic Drug Market by Distribution Channel
  • 3.4.1: Hospital Pharmacy
  • 3.4.2: Retail Pharmacy
  • 3.4.3: Online Pharmacy
• 3.5: Global Antipsychotic Drug Market by Application
  • 3.5.1: Schizophrenia
  • 3.5.2: Dementia
  • 3.5.3: Bipolar Disorder
  • 3.5.4: Depression
  • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Antipsychotic Drug Market by Region
• 4.2: North American Antipsychotic Drug Market
  • 4.2.1: North American Market by Therapeutic Class: First-generation and Second-generation
  • 4.2.2: North American Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others
• 4.3: European Antipsychotic Drug Market
  • 4.3.1: European Market by Therapeutic Class: First-generation and Second-generation
  • 4.3.2: European Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others
• 4.4: APAC Antipsychotic Drug Market
  • 4.4.1: APAC Market by Therapeutic Class: First-generation and Second-generation
  • 4.4.2: APAC Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others
• 4.5: ROW Antipsychotic Drug Market
  • 4.5.1: ROW Market by Therapeutic Class: First-generation and Second-generation
  • 4.5.2: ROW Market by Application: Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Antipsychotic Drug Market by Therapeutic Class
  • 6.1.2: Growth Opportunities for the Global Antipsychotic Drug Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Antipsychotic Drug Market by Application
  • 6.1.4: Growth Opportunities for the Global Antipsychotic Drug Market by Region
• 6.2: Emerging Trends in the Global Antipsychotic Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Antipsychotic Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Antipsychotic Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Alkermes
• 7.2: Eli Lilly and Company
• 7.3: Bristol-Myers Squibb
• 7.4: Otsuka Holdings
• 7.5: AbbVie
• 7.6: Johnson & Johnson
• 7.7: Teva Pharmaceutical Industries
• 7.8: Pfizer
• 7.9: Astrazeneca
• 7.10: Dr. Reddy's Laboratories